Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stannous chloride (tin(II) chloride, SnCl2) is an inorganic compound used primarily as a reducing agent in various industrial and pharmaceutical applications. In medicine, it serves as a component of technetium-99m radiopharmaceutical kits for diagnostic imaging. Stannous chloride acts by reducing technetium-99m to allow the formation of Tc99m-labeled complexes (such as Tc99m-pyrophosphate), which are then used for imaging areas of altered osteogenesis or detecting infarcted heart tissue. Stannous chloride itself does not have direct pharmacological effects at clinical dosages; its role is to facilitate the preparation of active radiopharmaceutical agents[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on stannous chloride.